SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ishita Drugs & Industries submits board meeting intimation

23 May 2025 Evaluate
Ishita Drugs & Industries has informed that pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the meeting of the Board of Directors of the Company will be held on Friday, 30th May, 2025 to transact the following business: 1. To consider, approve and take on records the Audited Financial Results of the Company for the quarter and year ended 31st March, 2025 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; 2.To consider and approve the Directors' Report with the Annexure, Corporate Governance Report, Management Discussion and Analysis Report and Notice for convening the 32nd Annual General Meeting of the Company; 3. To consider the appointment of Meenu Maheshwari & Associates, Practicing Company Secretary as the Secretarial Auditor of the Company for the year 2025-26; 4. To consider the re-appointment of Arvind Sapkal [DIN: 08607096] for the further term of Five years as an Independent Non-Executive Director of the Company; 5. To consider the re-appointment of Internal Auditors of the company for the year 2025-26; 6. To take on record Disclosure of interest of Directors; 7. Any other matter with permission of the chair. Further in accordance with Code of Conduct for Prevention of Insider Trading Framed by the Company pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the securities of the Company by Designated Persons of the Company (Code) stands closed from 1st April, 2025 till 48 hours from the announcement of the Audited Financial Results for the quarter and year ended 31st March, 2025.

The above information is a part of company’s filings submitted to BSE.


Ishita Drugs & Inds. Share Price

83.00 2.00 (2.47%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×